An update from Kiniksa Pharmaceuticals ( (KNSA) ) is now available.
Kiniksa Pharmaceuticals announced the termination of its license agreement with MedImmune for mavrilimumab, effective May 22, 2025, as part of a strategic reprioritization. The company also decided to discontinue the Phase 2b clinical trial of abiprubart in Sjögren’s Disease, incurring significant expenses related to contract termination costs. Despite these changes, Kiniksa reported strong financial results for 2024, with ARCALYST sales growing by 79% year-over-year, and plans to initiate a Phase 2/3 trial for KPL-387 in recurrent pericarditis in mid-2025.
More about Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel therapies for diseases with unmet needs, particularly in cardiovascular indications.
YTD Price Performance: -1.55%
Average Trading Volume: 460,177
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.42B
Find detailed analytics on KNSA stock on TipRanks’ Stock Analysis page.